Navigation Links
Lymph Node Shots Tested for Grass Pollen Allergy
Date:11/11/2008

Eight-week regimen better than 3 to 5 years of standard shots under skin, study finds

TUESDAY, Nov. 11 (HealthDay News) -- A Swiss-led study appears to point the way toward a faster, safer and less painful treatment for grass pollen allergy by using direct injections into the lymph node.

Compared with traditional under-the-skin shot regimens lasting several years and involving dozens of injections, the new method appears to offer patients the same degree of relief -- with fewer side effects -- with just three shots over two months.

"Because direct administration of the allergen into the lymph node markedly enhanced efficacy, the injected allergen dose could be reduced more than 1,000-fold, and this again significantly reduced the allergic side effects," said study co-author Dr. Thomas Kundig, medical director of the department of dermatology at University Hospital of Zurich.

Kundig and colleagues published their findings in this week's online edition of the Proceedings of the National Academy of Sciences.

The authors noted that allergic asthma affects upwards of 35 percent of those living in Westernized countries. To combat the problem, standard allergy shots -- injected in fatty tissue under the skin -- are considered the "gold standard" approach.

However, a typical shot regimen involves between 30 to 70 injections over three to five years, a time-consuming treatment that often provokes allergic reactions ranging from swelling at the shot site to systemic allergic reactions.

The result: "Less than 5 percent of allergy patients are treated with allergen-specific immunotherapy," Kundig said.

To test the potential of lymph node shots, the Swiss-American team focused on just under 100 patients between the ages of 18 and 65.

The volunteers were divided into two groups: those receiving a standard injection allergy treatment tracking a 54-injection schedule over a three-year period, and those receiving the lymph node therapy, which involved three injections over an eight-week period.

Kundig and his colleagues found that both approaches afforded similar benefits to the two groups of patients. However, those receiving the lymph node therapy experienced less pain and less frequent side effects than those undergoing conventional treatment.

After conducting nasal tests to assess allergy symptoms such as sneezing, nasal secretion, coughing, and shortness of breath, Kundig and his team concluded that their lymph node method proved to be both a shorter and safer treatment option compared with conventional shots. And they suggested that the relatively pain-free alternative could go a long way toward encouraging patients to stick with their anti-allergy treatment to the end.

"As the lymph node itself has no nerves, injection into a lymph node is painless," noted Kundig. "In fact, it was judged less painful than a blood draw. Overall, this treatment enhanced patient compliance, and the amelioration of hay fever symptoms was long lasting."

For his part, Dr. Clifford Bassett, a clinical instructor at New York University School of Medicine and attending physician in the allergy and immunology department of Long Island College Hospital in Brooklyn, N.Y., described the lymph node therapy as "quite novel" and "intriguing."

"I've never seen this type of approach before," noted Bassett, who is also the medical director of Allergy and Asthma Care of New York in New York City. "The allergens we're using now are certainly very potent and very effective. But we're obviously always looking at new ways to treat the epidemic of allergy. And there's a need for better treatment, and more cost-effective and safer treatment. So, this is a piece of information, although preliminary and focused only on grass pollen, that provides some insight into other ways to approach the problem."

More information

For more about pollen allergies, visit the U.S. National Institute of Environmental Health Sciences.



SOURCES: Thomas Kundig, M.D., medical director, department of dermatology, University Hospital of Zurich, Switzerland; Clifford Bassett, M.D., clinical instructor, New York University School of Medicine, New York City, attending physician, allergy and immunology department, Long Island College Hospital, Brooklyn, N.Y., and medical director, Allergy and Asthma Care of New York; Nov. 10-14, 2008, Proceedings of the National Academy of Sciences, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Researchers aim to over-stress already taxed mantle cell lymphoma cells
2. Silicone Breast Implants Might Raise Risk of Rare Lymphoma
3. Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
4. Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkins Lymphoma
5. Know Your L-Dex(TM) (Lymphedema Index) Awareness Campaign Attracts Large Numbers of Breast Cancer Survivors at Komen Race for the Cure(R) Events
6. MU study identifies patient strategies for managing symptoms of lymphedema
7. Poverty Raises Mortality Risk With Non-Hodgkin Lymphoma
8. Socioeconomic and treatment factors affect non-Hodgkin lymphoma patients survival
9. Hodgkin lymphoma -- new characteristics discovered
10. The Leukemia & Lymphoma Society Awards Major Grant to Stanford Researcher
11. Association for the Advancement of Wound Care Leads World Health Organization Initiative to Establish Guidelines for Wound and Lymphedema Care
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lymph Node Shots Tested for Grass Pollen Allergy
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology: